Katherine A. Guthrie
Fred Hutchinson Cancer Research Center
218 Papers
869 Citations
Katherine A. Guthrie is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Medicine & Transplantation. The author has an hindex of 56, co-authored 190 publications. Previous affiliations of Katherine A. Guthrie include University of Washington.
Chat about Author
Papers
NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).
Michael J. Overman,Greg Yothers,Samuel A. Jacobs,Hanna K. Sanoff,Deirdre Jill Cohen,Katherine A. Guthrie,Norah Lynn Henry,Patricia A. Ganz,Scott Kopetz,Peter C. Lucas,Charles D. Blanke,Norman Wolmark,Howard S. Hochster,Thomas J. George,Caio Max Sao Pedro Rocha Lima +14 more
TL;DR: This data indicates that despite activity of programmed cell death-1 (PD-1) pathway inhibition in dMMR/MSI-H mCRC, approximately one-third of patients demonstrate progressive disease as best response to a single therapy.
8
Improved immunomagnetic enrichment of CD34+ cells from umbilical cord blood using the CliniMACS cell separation system
Joseph Blake,Ian B. Nicoud,Daniel Weber,Howard Voorhies,Katherine A. Guthrie,Shelly Heimfeld,Colleen Delaney,Colleen Delaney +7 more
TL;DR: For CD34(+) enrichment from fresh CBU, LS provided higher post-selection viability and more efficient recovery, and the same may hold for smaller scale enrichment of other cell types with the CliniMACS instrument.
8
The Mantle Cell Lymphoma International Prognostic Index (MIPI) at Diagnosis Is Associated with Survival of Mantle Cell Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.
Lihua Pan,Katherine A. Guthrie,Brian G. Till,Oliver W. Press,John M. Pagel,Stephen H. Petersdorf,William I. Bensinger,Leona Holmberg,David G. Maloney,Ajay K. Gopal +9 more
TL;DR: The results indicate that the MIPI-Dx is a robust prognostic tool that can even be used to predict outcomes after a later transplant, suggesting that it may continue to reflect the biology of an individual patient’s disease over time.
7
Abstract of the 20th International Anniversary MASCC/ISOO Symposium: A Phase III randomized double-blind placebo controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation
Mark M. Schubert,Fernanda de Paula Eduardo,Katherine A. Guthrie,J. C. Franquin,René-Jean Bensadoun,Cesar A. Migliorati,M. Hamdi,W. Niccoli-Filho +7 more
7
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.
Michael J. Overman,Greg Yothers,Samuel A. Jacobs,Hanna K. Sanoff,Deirdre Jill Cohen,Katherine A. Guthrie,Norah Lynn Henry,Patricia A. Ganz,Scott Kopetz,Peter C. Lucas,Charles D. Blanke,Norman Wolmark,Howard S. Hochster,Thomas J. George,Caio Max Sao Pedro Rocha Lima +14 more
TL;DR: It is hypothesized that the dMMR/MSI-H mCRC patients may be more effectively treated by the combination of PD-1 pathway blockade and mFOLFOX6/bevacizumab (bev) rather than with anti-PD-L1 therapy (atezo) alone.
7